Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3226211#aggregation> ?p ?o. }
Showing items 1 to 45 of
45
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B448413.
- aggregation creator B448414.
- aggregation creator B448415.
- aggregation creator B448416.
- aggregation creator B448417.
- aggregation creator B448418.
- aggregation creator B448419.
- aggregation creator B448420.
- aggregation creator B448421.
- aggregation creator B448422.
- aggregation creator B448423.
- aggregation creator B448424.
- aggregation creator B448425.
- aggregation creator person.
- aggregation date "2012".
- aggregation format "application/pdf".
- aggregation hasFormat 3226211.bibtex.
- aggregation hasFormat 3226211.csv.
- aggregation hasFormat 3226211.dc.
- aggregation hasFormat 3226211.didl.
- aggregation hasFormat 3226211.doc.
- aggregation hasFormat 3226211.json.
- aggregation hasFormat 3226211.mets.
- aggregation hasFormat 3226211.mods.
- aggregation hasFormat 3226211.rdf.
- aggregation hasFormat 3226211.ris.
- aggregation hasFormat 3226211.txt.
- aggregation hasFormat 3226211.xls.
- aggregation hasFormat 3226211.yaml.
- aggregation isPartOf urn:issn:0140-6736.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial".
- aggregation abstract "Background : The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet. We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection. Methods : This phase 3, non-inferiority study enrolled treatment-naive patients with an HIV-1 RNA concentration of 5000 copies per mL or more and susceptibility to atazanavir, emtricitabine, and tenofovir. Patients were randomly assigned (1: 1) to receive EVG/COBI/FTC/TDF or ATV/RTV+FTC/TDF plus matching placebos, administered once daily. Randomisation was by a computer-generated random sequence, accessed via an interactive telephone and web response system. Patients, and investigators and study staff who gave treatments, assessed outcomes, or analysed data were masked to the assignment. The primary endpoint was HIV RNA concentration of 50 copies per mL or less after 48 weeks (according to the US FDA snapshot algorithm), with a 12% non-inferiority margin. This trial is registered with ClinicalTrials.gov, number NCT01106586. Findings : 1017 patients were screened, 715 were enrolled, and 708 were treated (353 with EVG/COBI/FTC/TDF and 355 with ATV/RTV+FTC/TDF). EVG/COBI/FTC/TDF was non-inferior to ATV/RTV+FTC/TDF for the primary outcome (316 patients [89.5%] vs 308 patients [86.8%], adjusted difference 3.0%, 95% CI -1.9% to 7.8%). Both regimens had favourable safety and tolerability; 13 (3.7%) versus 18 (5.1%) patients discontinued treatment because of adverse events. Fewer patients receiving EVG/COBI/FTC/TDF had abnormal results in liver function tests than did those receiving ATV/RTV+FTC/TDF and had smaller median increases in fasting triglyceride concentration (90 mu mol/L vs 260 mu mol/L, p=0.006). Small median increases in serum creatinine concentration with accompanying decreases in estimated glomerular filtration rate occurred in both study groups by week 2; they generally stabilised by week 8 and did not change up to week 48 (median change 11 mu mol/L vs 7 mu mol/L). Interpretation : If regulatory approval is given, EVG/COBI/FTC/TDF would be the first integrase-inhibitor-based regimen given once daily and the only one formulated as a single tablet for initial HIV treatment.".
- aggregation authorList BK781679.
- aggregation endPage "2438".
- aggregation issue "9835".
- aggregation startPage "2429".
- aggregation volume "379".
- aggregation aggregates 3233221.
- aggregation isDescribedBy 3226211.
- aggregation similarTo S0140-6736(12)60918-0.
- aggregation similarTo LU-3226211.